These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9230143)

  • 1. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease.
    Brown BG; Bardsley J; Poulin D; Hillger LA; Dowdy A; Maher VM; Zhao XQ; Albers JJ; Knopp RH
    Am J Cardiol; 1997 Jul; 80(2):111-5. PubMed ID: 9230143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
    Zambon A; Hokanson JE; Brown BG; Brunzell JD
    Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
    Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
    Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia.
    Malloy MJ; Kane JP; Kunitake ST; Tun P
    Ann Intern Med; 1987 Nov; 107(5):616-23. PubMed ID: 3662275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
    Kashyap ML; McGovern ME; Berra K; Guyton JR; Kwiterovich PO; Harper WL; Toth PD; Favrot LK; Kerzner B; Nash SD; Bays HE; Simmons PD
    Am J Cardiol; 2002 Mar; 89(6):672-8. PubMed ID: 11897208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin.
    Gardner SF; Schneider EF; Granberry MC; Carter IR
    Pharmacotherapy; 1996; 16(3):419-23. PubMed ID: 8726600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data.
    Armstrong EP; Zachry WM; Malone DC
    J Manag Care Pharm; 2004; 10(3):251-8. PubMed ID: 15228376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of niacin, statins, and resins in patients with combined hyperlipidemia.
    Brown BG; Zambon A; Poulin D; Rocha A; Maher VM; Davis JW; Albers JJ; Brunzell JD
    Am J Cardiol; 1998 Feb; 81(4A):52B-59B. PubMed ID: 9526815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
    Morgan JM; Capuzzi DM; Guyton JR
    Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination drug therapy for hypercholesterolemia. The trade-off between cost and simplicity.
    Heudebert GR; Van Ruiswyk J; Hiatt J; Schectman G
    Arch Intern Med; 1993 Aug; 153(15):1828-37. PubMed ID: 8333817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia.
    Gupta EK; Ito MK
    Heart Dis; 2002; 4(2):124-37. PubMed ID: 11975844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy.
    Schrott HG; Stein EA; Dujovne CA; Davidson MH; Goris GB; Oliphant TH; Phillips JC; Shawaryn GG
    Am J Cardiol; 1995 Jan; 75(1):34-9. PubMed ID: 7801861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
    Barbir M; Hunt BJ; Galloway D; Taylor A; Ilsley C; Mitchell A; Yacoub M
    Clin Cardiol; 1994 Feb; 17(2):59-64. PubMed ID: 8162627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
    Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ
    J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia.
    Jelesoff NE; Ballantyne CM; Xydakis AM; Chiou P; Jones PH; Guyton JR
    Endocr Pract; 2006; 12(2):159-64. PubMed ID: 16690463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.